拜耳全球高管：中国正成为全球生物医药创新重要源头

Group 1 - China is becoming a significant source of global biopharmaceutical innovation, with immense potential for its innovations to reach global markets [1][3] - Bayer views China as a core strategic market and a crucial growth engine, having been present in the country for over 140 years [3][6] - The Chinese biopharmaceutical industry is transitioning from being an "innovator follower" to a "source of innovation," currently holding about 30% of the global pipeline [3][4] Group 2 - The rapid approval process for clinical trials and new drug applications in China is enhancing the speed at which innovative therapies reach patients [4][5] - Bayer Co.Lab has launched a venture alliance in Shanghai, marking a significant upgrade in its collaborative ecosystem to empower local innovations [5] - Bayer has established partnerships with renowned academic institutions like Tsinghua University and Peking University, conducting over 100 joint research projects to facilitate the transition from basic research to new drug development [5]